Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:02 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
13,809,601 | 13,513,423 | 13,405,240 | 12,654,860 | 13,487,200 |
Cost of Goods Sold (COGS) incl. D&A |
4,737,620 | 4,403,726 | 4,320,643 | 4,131,371 | 4,670,015 |
COGS excluding D&A |
3,448,675 | 3,217,848 | 3,201,587 | 3,077,337 | 3,994,788 |
Depreciation & Amortization Expense |
1,288,945 | 1,185,877 | 1,119,055 | 1,054,034 | 675,226 |
Gross Income |
9,071,980 | 9,109,696 | 9,084,597 | 8,523,488 | 8,817,185 |
SG&A Expense |
6,762,308 | 6,042,008 | 6,218,539 | 5,941,841 | 6,684,746 |
Research & Development |
2,440,987 | 2,108,975 | 2,141,576 | 2,059,236 | 2,302,158 |
Other SG&A |
4,321,321 | 3,933,032 | 4,076,962 | 3,882,605 | 4,382,587 |
Other Operating Expense |
483,354 | 434,115 | 349,587 | 475,421 | 1,209,021 |
Unusual Expense |
439,582 | 191,550 | 35,614 | 191,642 | 1,356,841 |
Non Operating Income/Expense |
906,173 | 404,276 | 538,908 | 641,265 | 1,624,194 |
Interest Expense |
185,332 | 171,336 | 171,513 | 151,102 | 158,769 |
Gross Interest Expense |
185,332 | 171,336 | 171,513 | 151,102 | 158,769 |
Pretax Income |
2,107,575 | 2,674,962 | 2,848,250 | 2,404,745 | 1,032,002 |
Income Tax |
324,099 | 369,624 | 451,746 | 378,678 | 46,535 |
Equity in Affiliates |
155,530 | 77,967 | 164,952 | 117,933 | 118,620 |
Consolidated Net Income |
1,939,006 | 2,383,306 | 2,561,457 | 2,144,001 | 1,104,087 |
Minority Interest Expense |
34,458 | 25,989 | 25,305 | 20,269 | 31,936 |
Net Income |
1,904,547 | 2,357,316 | 2,536,151 | 2,123,731 | 1,072,150 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
1,904,547 | 2,357,316 | 2,536,152 | 2,123,731 | 1,072,150 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
1,904,547 | 2,357,316 | 2,536,151 | 2,123,731 | 1,072,150 |
Operational EPS |
0.90 | 1.02 | 1.05 | 0.93 | 0.83 |
EPS (basic) |
0.79 | 0.97 | 1.05 | 1.00 | 0.45 |
EBITDA |
3,115,262 | 3,819,450 | 3,635,526 | 3,160,259 | 1,598,645 |
Depreciation & Amortization Expense |
1,288,945 | 1,185,877 | 1,119,055 | 1,054,034 | 675,226 |
Common Shares Outstanding |
2,418,000 | 2,418,500 | 2,420,700 | 2,414,600 | 2,412,600 |
Basic Shares Outstanding |
2,418,000 | 2,418,500 | 2,420,700 | 2,414,600 | 2,412,600 |
Diluted Shares Outstanding |
2,445,000 | 2,444,500 | 2,441,200 | 2,435,100 | 2,436,800 |
Diluted EPS after Extraordinary Items |
0.78 | 0.96 | 1.04 | 0.87 | 0.44 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.79 | 0.97 | 1.05 | 0.88 | 0.45 |
*Figures in thousands of U.S. Dollars except shares outstanding.
